Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Neuro-immunology
How does progression independent of relapse activity (PIRMA) influence your decision to change treatment in relapsing remitting multiple sclerosis?
Related Questions
What are your vaccine recommendations while patients are on biologics?
What is your approach to treatment when there is a multiple sclerosis reactivation while on natalizumab?
At what degree of lymphopenia do you switch/discontinue dimethyl fumarate in patients with multiple sclerosis?
How do you counsel women on anti-CD20 therapy for MS who are planning for pregnancy?
When do you suspect an autoimmune encephalitis in a child or adolescent with new-onset psychosis?
Do you have any clinical experience regarding the administration of B cell depleting therapies in MS patients with splenectomy?
How do you decide on long term immunosuppression therapy for Susac Syndrome?
In a patient with prior biopsy-proven IgG4-related pachymeningitis who develops recurrent neurologic symptoms years after discontinuing immunosuppression, how do you determine whether this represents relapse versus alternative etiologies?
When should patients be referred for advanced MRI testing to assess for CVS and PRL?
When should MOG-Ab be tested in patients with suspected autoimmune encephalitis with seizures and normal MRI?
